NMIBC is becoming more prominent as its incidence is correlated with older age groups, with the median age being 70 when ...

The Danish multinational said that Sogroya improved the yearly growth rate in pre-pubertal children born small for ...

LEO Pharma has reported topline outcomes from the Phase IIb trial of temtokibart, a potential new treatment for atopic ...

Vir is holding off on advancing the combination therapy to Phase III trials in hepatitis B until it secures a development ...

Johnson & Johnson (J&J) has reported new data from the Phase III ICONIC-TOTAL trial, assessing icotrokinra in treating plaque ...

GSK has reported positive outcomes from the Phase III GLISTEN trial of linerixibat for cholestatic pruritus (itch) and PBC.

AstraZeneca and Daiichi's Enhertu, followed by THP, has shown pCR rate improvement in the randomised DESTINY-Breast11 Phase ...

It is vital for biotech companies to run the right clinical trial and not cut costs, the Sanofi executive said.

Boehringer Ingelheim has begun the JADE Phase II trial to evaluate BI 1584862 as a first-in-class oral treatment for ...

Gilead Sciences has reported final outcomes from the Phase III MYR301 trial of bulevirtide for adults with chronic hepatitis ...

OmRx Oncology (OmRx) has commenced a Phase II trial for its OX-4224, targeting individuals with non-small cell lung cancer ...

Tempus AI has announced that it is using the TIME Network for Phase I trials to expedite site activation and enrolment.